Kucharska Anna M, Majcher Anna, Rymkiewicz-Kluczyńska Barbara
Katedra i Klinika Pediatrii i Endokrynologii AM w Warszawie.
Pediatr Endocrinol Diabetes Metab. 2007;13(3):165-70.
Growth hormone treatment in Turner girls is a widely accepted method of their final height improvement. However some patients do not reach satisfactory final height. The aim of the study was to evaluate the anthropometric parameters which would be prognostic for final height in children with Turner syndrome treated with growth hormone.
Data of 18 girls with Turner syndrome who completed growth hormone therapy and reached a final height were analysed. Mean age was 11.32+/-3.04 years. Correlations of final height with following parameters were analysed: trunk to limbs ratio, lower limbs length (in SDS), growth velocity in the first years of GH therapy. From among other characteristics which could determine the final height the karyotype, age at the start of GH therapy were evaluated.
The mean height gain in the group was 8.4 cm (range: 0.6-19.9 cm). Final height over 3rd percentile for the healthy population achieved 33.3% patients. Growth velocity in first 2 years of therapy correlated negatively with final height. Patients with final height over 3rd percentile had statistically significant greater mean height gain. Patients with low final height had a significantly greater deficit of leg length and increased Trunk/Leg Length index. Age at the beginning and duration of therapy had no influence on final height.
Better final height reach the patients who have more advantageous Trunk/Leg Length index before and during therapy, and reduction of leg length deficiency is relatively greater than height deficiency reduction.
对特纳综合征女童进行生长激素治疗是一种被广泛认可的改善其最终身高的方法。然而，一些患者并未达到令人满意的最终身高。本研究的目的是评估那些对接受生长激素治疗的特纳综合征患儿的最终身高具有预后价值的人体测量参数。
分析了18例完成生长激素治疗并达到最终身高的特纳综合征女童的数据。平均年龄为11.32±3.04岁。分析了最终身高与以下参数的相关性：躯干与四肢比例、下肢长度（以标准差计分）、生长激素治疗最初几年的生长速度。从其他可能决定最终身高的特征中，评估了核型、开始生长激素治疗时的年龄。
该组的平均身高增长为8.4厘米（范围：0.6 - 19.9厘米）。最终身高超过健康人群第3百分位数的患者占33.3%。治疗前两年的生长速度与最终身高呈负相关。最终身高超过第3百分位数的患者平均身高增长在统计学上显著更高。最终身高较低的患者腿部长度明显更短，且躯干/腿长指数增加。治疗开始时的年龄及治疗持续时间对最终身高无影响。
治疗前及治疗期间躯干/腿长指数更有利、腿部长度不足减少相对大于身高不足减少的患者，最终身高更好。
